logo-loader

IPO Roundup: Chinese live-streaming platform DouYu leads off international-heavy week of IPOs

Also going public this week are Danish biotechnology company Genmab A/S and Peruvian wealth-management company Intercorp Financial Services

Black blocks that read 'I', 'P' and 'O'
DoYu has the biggest user base and the highest level of user engagement among live-stream platforms in China

A bevy of companies are slated to make their public debuts this week, led by a series of international companies.

Pricing Tuesday night

DouYu International Holdings Ltd (NASDAQ:DOYU), a Chinese video game live-streaming platform, expects to bring in $859 million by offering 67.4 million shares between $11.50 and $14. The company has the biggest user base and the highest level of user engagement among live-stream platforms in China, according to iResearch.

Pricing Wednesday night

Genmab A/S (NASDAQ:GMAB), a biotechnology company based in Copenhagen, plans to offer 27.8 million shares at $18.11 per share to raise $503 million. The company is focused on creating antibody treatments for cancer and other diseases, and it plans to launch a proprietary product by 2025. Its pipeline includes five products in clinical development and about 20 proprietary and partnered pre-clinical programs.

AssetMark Financial Holdings Inc (NYSE:AMK), a wealth-management and technology-solutions company based in Concord, California, expects to offer 12.5 million shares between $19 and $21 per share in a bid to raise $250 million. Its platform provides tools to independent financial advisors and their clients.

Phreesia Inc (NASDAQ:PHR), a patient-intake software provider for healthcare companies, hopes to rake in $125 million by offering 7.8 million shares between $15 and $17 per share. The New York company’s namesake SaaS platform offers a patient-intake management system and an integrated-payments system.

Fulcrum Therapeutics Inc (NASDAQ:FULC), a clinical-stage biopharmaceutical company, is looking to raise $77 million by offering 4.5 million shares between $16 and $18. The Cambridge, Massachusetts company is focused on rare genetically defined diseases. Losmapimod, its product candidate for facioscapulohumeral muscular dystrophy, is expected to be part of a Phase 2b clinical trial in mid 2019.

Mirum Pharmaceuticals Inc (NASDAQ:MIRM), a Foster City, California-based biopharmaceutical company, plans to raise $75 million by offering 5 million shares between $14 and $16. Its treatment pipeline consists of a pair of clinical-stage candidates to treat progressive familial intrahepatic cholestasis and Alagille syndrome, disorders that affect the liver.

Pricing Thursday night

Intercorp Financial Services Inc (NASDAQ:IFS), a Peruvian wealth-management company, hopes to raise $423 million by offering 9 million shares between $44 and $50 per share. The company’s digital platform and distribution network offers its 3 million customers access to its banking, insurance and wealth-management products and services.

Afya Ltd (NASDAQ:AFYA), a Brazilian healthcare education company, hopes to raise $234 million by offering 13.7 million shares between $16 and $18 per share. Its network, the largest in Brazil, is made up of 14 undergraduate and graduate medical school campuses with 9 operating units and 5 approved units.

Medallia Inc (NASDAQ:MDLA), an enterprise software company from San Francisco, expects to offer 14.5 million shares between $16 and $18 per share to raise $247 million. Its signature SaaS platform, the Medallia Experience Cloud, helps businesses gather data from their customers and deliver insight in real time.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

2 days ago

3 min read